Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Brain-Derived Neurotrophic Factor Prevents Depressive-Like Behaviors in Early-Symptomatic YAC128 Huntington's Disease Mice.

da Fonsêca VS, da Silva Colla AR, de Paula Nascimento-Castro C, Plácido E, Rosa JM, Farina M, Gil-Mohapel J, Rodrigues ALS, Brocardo PS.

Mol Neurobiol. 2018 Sep;55(9):7201-7215. doi: 10.1007/s12035-018-0890-6. Epub 2018 Jan 31.

PMID:
29388082
2.

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.

de Paula Nascimento-Castro C, Wink AC, da Fônseca VS, Bianco CD, Winkelmann-Duarte EC, Farina M, Rodrigues ALS, Gil-Mohapel J, de Bem AF, Brocardo PS.

Neural Plast. 2018 Aug 14;2018:4056383. doi: 10.1155/2018/4056383. eCollection 2018.

3.

Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.

Silva AC, Ferreira IL, Hayden MR, Ferreiro E, Rego AC.

Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):34-44. doi: 10.1016/j.bbadis.2017.09.009. Epub 2017 Sep 20.

4.

Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice.

McGregor AL, D'Souza G, Kim D, Tingle MD.

Neuropharmacology. 2017 Apr;116:233-246. doi: 10.1016/j.neuropharm.2016.12.021. Epub 2016 Dec 23.

PMID:
28025093
5.

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W.

Exp Neurol. 2008 Mar;210(1):154-63. Epub 2007 Nov 9.

6.

Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease.

Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR.

Neurobiol Dis. 2011 Feb;41(2):249-60. doi: 10.1016/j.nbd.2010.09.012. Epub 2010 Sep 25.

PMID:
20875859
7.

Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine.

Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, Hannan AJ.

Eur J Neurosci. 2005 Oct;22(8):2081-8.

PMID:
16262645
8.

Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.

Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ.

J Neurosci. 2004 Mar 3;24(9):2270-6.

9.

Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models.

Schmidt HD, Duman RS.

Neuropsychopharmacology. 2010 Nov;35(12):2378-91. doi: 10.1038/npp.2010.114. Epub 2010 Aug 4. Erratum in: Neuropsychopharmacology. 2011 Jan;36(2):550.

10.

Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.

Jeon J, Kim W, Jang J, Isacson O, Seo H.

Neuroscience. 2016 Jun 2;324:20-8. doi: 10.1016/j.neuroscience.2016.02.054. Epub 2016 Mar 2.

PMID:
26944602
11.

Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.

Zajac MS, Pang TY, Wong N, Weinrich B, Leang LS, Craig JM, Saffery R, Hannan AJ.

Hippocampus. 2010 May;20(5):621-36. doi: 10.1002/hipo.20658.

PMID:
19499586
12.

YAC128 Huntington's disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease.

Ghilan M, Bostrom CA, Hryciw BN, Simpson JM, Christie BR, Gil-Mohapel J.

Brain Res. 2014 Sep 18;1581:117-28. doi: 10.1016/j.brainres.2014.06.011. Epub 2014 Jun 17.

PMID:
24949563
13.

The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors.

Schamne MG, Mack JM, Moretti M, Matheus FC, Walz R, Lanfumey L, Prediger RD.

Neurotox Res. 2018 Nov;34(4):808-819. doi: 10.1007/s12640-018-9912-4. Epub 2018 May 28.

PMID:
29808370
14.

Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism.

Madison JL, Wegrzynowicz M, Aschner M, Bowman AB.

PLoS One. 2012;7(2):e31024. doi: 10.1371/journal.pone.0031024. Epub 2012 Feb 17.

15.

Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.

Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, Kvann JC, Tomaszewski M, Beaubien F, Cloutier JF, Levesque D, Sadikot AF.

Genes Brain Behav. 2013 Feb;12(1):108-24. doi: 10.1111/j.1601-183X.2012.00858.x. Epub 2012 Nov 21.

16.

Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.

Pang TY, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ.

Neuroscience. 2006 Aug 25;141(2):569-84. Epub 2006 May 22.

PMID:
16716524
17.

Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.

Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR.

J Neurosci. 2005 Apr 20;25(16):4169-80.

18.

Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.

Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA.

Exp Neurol. 2016 Nov;285(Pt A):12-23. doi: 10.1016/j.expneurol.2016.08.012. Epub 2016 Aug 29.

PMID:
27587303
19.

Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity.

Anglada-Huguet M, Vidal-Sancho L, Giralt A, García-Díaz Barriga G, Xifró X, Alberch J.

Neurobiol Dis. 2016 Nov;95:22-34. doi: 10.1016/j.nbd.2015.09.001. Epub 2015 Sep 11.

PMID:
26369879

Supplemental Content

Support Center